Orange, CONNECTICUT27 Active Studies

Alzheimers Disease Clinical Trials in Orange, CONNECTICUT

Find 27 actively recruiting alzheimers disease clinical trials in Orange, CONNECTICUT. Connect with local research sites and explore new treatment options.

27
Active Trials
21
Sponsors
11,881
Enrolling

Recruiting Alzheimers Disease Studies in Orange

RecruitingOrange, CONNECTICUTNCT03486873

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

3,500 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingOrange, CONNECTICUTNCT06129864

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HN...

1,145 participants
AstraZeneca
View Study Details
RecruitingOrange, CONNECTICUTNCT06225596

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monothe...

956 participants
BicycleTx Limited
View Study Details
RecruitingOrange, CONNECTICUTNCT06319820

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of ...

560 participants
Janssen Research & Development, LLC
View Study Details
RecruitingOrange, CONNECTICUTNCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

500 participants
Turning Point Therapeutics, Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT06510374

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

454 participants
Ferring Pharmaceuticals
View Study Details
RecruitingOrange, CONNECTICUTNCT05410145

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

442 participants
D3 Bio (Wuxi) Co., Ltd
View Study Details
RecruitingOrange, CONNECTICUTNCT06585787

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD....

406 participants
Karuna Therapeutics
View Study Details
RecruitingOrange, CONNECTICUTNCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in ...

400 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT06264180

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage III...

400 participants
Replimune Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the st...

380 participants
Karuna Therapeutics
View Study Details
RecruitingOrange, CONNECTICUTNCT06567743

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer....

325 participants
CG Oncology, Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT06973577

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety...

308 participants
Otsuka Pharmaceutical Development & Commercialization, Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT06887192

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucination...

300 participants
MapLight Therapeutics
View Study Details
RecruitingOrange, CONNECTICUTNCT06545955

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

250 participants
Ferring Pharmaceuticals
View Study Details
RecruitingOrange, CONNECTICUTNCT06211764

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose...

250 participants
Janssen Research & Development, LLC
View Study Details
RecruitingOrange, CONNECTICUTNCT06125951

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the...

220 participants
Actinogen Medical
View Study Details
RecruitingOrange, CONNECTICUTNCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...

190 participants
AstraZeneca
View Study Details
RecruitingOrange, CONNECTICUTNCT04671667

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with...

188 participants
National Cancer Institute (NCI)
View Study Details
RecruitingOrange, CONNECTICUTNCT03375307

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other pla...

150 participants
National Cancer Institute (NCI)
View Study Details
RecruitingOrange, CONNECTICUTNCT05951179

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1...

127 participants
Protara Therapeutics
View Study Details
RecruitingOrange, CONNECTICUTNCT04068194

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and ...

103 participants
National Cancer Institute (NCI)
View Study Details
RecruitingOrange, CONNECTICUTNCT06828861

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The...

90 participants
Aardvark Therapeutics, Inc.
View Study Details
RecruitingOrange, CONNECTICUTNCT05491525

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC...

85 participants
Urovant Sciences GmbH
View Study Details
RecruitingOrange, CONNECTICUTNCT05038150

Study of SGN1 in Patients With Advanced Solid Tumor

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...

70 participants
Guangzhou Sinogen Pharmaceutical Co., Ltd
View Study Details
RecruitingOrange, CONNECTICUTNCT06874621

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug...

52 participants
Voyager Therapeutics
View Study Details
RecruitingOrange, CONNECTICUTNCT04929236

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

30 participants
Octapharma
View Study Details

About Alzheimers Disease Clinical Trials in Orange

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 27 alzheimers disease clinical trials recruiting participants in Orange, CONNECTICUT. These studies are seeking a combined 11,881 participants. Research is being sponsored by Merck Sharp & Dohme LLC, AstraZeneca, BicycleTx Limited and 18 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in Orange — FAQ

Are there alzheimers disease clinical trials in Orange?

Yes, there are 27 alzheimers disease clinical trials currently recruiting in Orange, CONNECTICUT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orange?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you about next steps.

Are clinical trials in Orange free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orange studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 27 active trials in Orange are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated March 2, 2026 from ClinicalTrials.gov